Orthofix has reported positive data from a clinical study of its Trinity Elite cellular bone allograft (CBA).

The prospective, multicentre study was designed for assessing the efficacy and safety of Trinity Elite CBA in lumbar spinal fusion procedures.

Trinity Elite is said to be a cryopreserved CBA from allograft donor bone which enables bone formation by providing an osteoconductive scaffold, inherent osteoinductive growth factors and osteogenic cells.

The findings, published in Neurology International, showed that the use of Trinity Elite CBA has resulted in 98.6% fusion rates, which are measured by bridging bone at 12 months follow-up using thin-cut CT scans.

In the clinical trial, the Trinity Elite allograft was assessed in participants undergoing posterolateral fusion or interbody fusion with CBA.

The study enrolled 274 participants, of whom 201 completed follow-up for 12 months and provided the data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An independent evaluation of dynamic radiographs and CT images was used to determine the radiographic fusion status.

Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain were used as clinical outcome measures.

Orthofix Global Spine president Kevin Kenny said: “We are pleased to continue to invest in clinical research and provide physicians the information they need to make the best decisions for their patients.

“The results of this publication support Trinity Elite as a safe and efficacious alternative to autograft for patients undergoing lumbar fusion procedures and demonstrate the compelling benefits of this cellular bone allograft.

“Trinity Elite is a key example of our commitment to deliver evidence-based, quality-driven solutions that can improve patients’ lives.”

The company stated that Trinity Elite removes the need for collecting autografts from patients. It saves operating time and reduces expense and discomfort as well as potential complications.

Trinity Elite, processed by MTF Biologics, is a moldable bone graft material which allows doctors to easily manage the placement of tissue during the process.